Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Aug 10;28(1):278.
doi: 10.1186/s40001-023-01238-9.

Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis

Arman Shafiee  1   2 , Mohammad Javad Amini  2 , Razman Arabzadeh Bahri  3 , Kyana Jafarabady  2 , Seyyed Amirhossein Salehi  4 , Hamed Hajishah  5 , Sayed-Hamidreza Mozhgani  6   7
Affiliations
Meta-Analysis

Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis

Arman Shafiee et al. Eur J Med Res. .

Abstract

Background: The reactivation of herpesviruses (HHV) in COVID-19 patients is evident in the literature. Several reports have been published regarding the reactivation of these viruses (HSV, VZV, EBV, and CMV) among those who got COVID-19 vaccines. In this study, we aimed to review the current evidence to assess whether HHVs reactivation has any association with the prior administration of COVID-19 vaccines.

Methods: A systematic search was conducted on 25 September 2022 in PubMed/MEDLINE, Web of Science, and EMBASE. We included all observational studies, case reports, and case series which reported the reactivation of human herpesviruses following administration of COVID-19 vaccines.

Results: Our systematic search showed 80 articles that meet the eligibility criteria. Among the evaluated COVID-19 vaccines, most of the vaccines were mRNA based. Evidence from observational studies showed the possible relation between COVID-19 vaccine administration and VZV and HSV reactivation. The results of our proportion meta-analysis showed that the rate of VZV reactivation among those who received the COVID-19 vaccine was 14 persons per 1000 vaccinations (95% CI 2.97-32.80). Moreover, our meta-analysis for HSV reactivation showed the rate of 16 persons per 1000 vaccinations (95% CI 1.06-46.4). Furthermore, the evidence from case reports/series showed 149 cases of HHV reactivation. There were several vaccines that caused reactivation including BNT162b2 mRNA or Pfizer-BioNTech (n = 76), Oxford-AstraZeneca (n = 22), mRNA-1273 or Moderna (n = 17), Sinovac (n = 4), BBIBP-CorV or Sinopharm (n = 3), Covaxin (n = 3), Covishield (n = 3), and Johnson and Johnson (n = 1). Reactivated HHVs included varicella-zoster virus (VZV) (n = 114), cytomegalovirus (CMV) (n = 15), herpes simplex virus (HSV) (n = 14), Epstein-Barr virus (EBV) (n = 6), and HHV-6 (n = 2). Most cases reported their disease after the first dose of the vaccine. Many patients reported having comorbidities, of which hypertension, diabetes mellitus, dyslipidemia, chicken pox, and atrial fibrillation were common.

Conclusion: In conclusion, our study showed the possible association between COVID-19 vaccination and herpesvirus reactivation. The evidence for VZV and HSV was supported by observational studies. However, regarding other herpesviruses (EBV and CMV), further research especially from observational studies and clinical trials is required to elucidate the interaction between COVID-19 vaccination and their reactivation.

Keywords: COVID-19; HHV; Herpesvirus; SARS-CoV-2; Vaccination.

PubMed Disclaimer

Conflict of interest statement

No conflict of interest is declared.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram for article selection
Fig. 2
Fig. 2
The results of the meta-analysis: A varicella-zoster virus. B herpes simplex virus
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Han F, et al. Current treatment strategies for COVID-19 (Review) Mol Med Rep. 2021 doi: 10.3892/mmr.2021.12498. - DOI - PMC - PubMed
    1. Shafiee A, et al. Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients. Virol J. 2022;19(1):102. doi: 10.1186/s12985-022-01829-8. - DOI - PMC - PubMed
    1. Cheema HA, et al. No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis. J Infect. 2022 doi: 10.1016/j.jinf.2022.11.022. - DOI - PMC - PubMed
    1. Loubet P, et al. A french cohort for assessing COVID-19 vaccine responses in specific populations. Nat Med. 2021;27(8):1319–1321. doi: 10.1038/s41591-021-01435-1. - DOI - PubMed
    1. Pormohammad A, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines (Basel) 2021 doi: 10.3390/vaccines9050467. - DOI - PMC - PubMed